The pharmacological properties of cyclohexanecarboxylic acid, {2-[4-(2-bromo-5-methoxybenzyl)piperazin-1-yl]ethyl}-(2-trifluoromethoxyphenyl)amide (Rec 27/0224), and cyclohexanecarboxylic acid, (2-methoxy-phenyl)-{2-[4-(2-methoxyphenyl)-piperazin-1-yl]ethyl}amide (Rec 27/0074), were characterized using radioligand displacement and guanosine 5Ј-O-(3-
-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-2-pyridinylcyclo-hexanecarboxamide (WAY-100635).Impairment of 5-hydroxytryptamine (5-HT) neurotransmission is involved in major neuropsychiatric pathological states (e.g., depression, anxiety, schizophrenia, and Parkinson's disease). Considerable effort has been consistently made to understand the functioning of the 5-HT system and to develop new selective drugs for 5-HT receptor subtypes.The 5-HT 1A receptor has been extensively studied because of the early discovery of a selective agonist (Gozlan et al., 1983) and receptor cloning (Kobilka et al., 1987;Albert et al., 1990). 5-HT 1A receptors are G protein-coupled receptors (GPCR) expressed throughout the central nervous system (Pompeiano et al., 1992). Stimulation of 5-HT 1A receptors activates Gi/o proteins, leading to at least two different cellular responses: inhibition of adenylate cyclase and opening Article, publication date, and citation information can be found at